Loading…

Profiling the antibody response of humans protected by immunization with Plasmodium vivax radiation-attenuated sporozoites

Malaria sterile immunity has been reproducibly induced by immunization with Plasmodium radiation-attenuated sporozoites (RAS). Analyses of sera from RAS-immunized individuals allowed the identification of P. falciparum antigens, such as the circumsporozoite protein (CSP), the basis for the RTS, S an...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports 2024-02, Vol.14 (1), p.2790-2790, Article 2790
Main Authors: Lopez-Perez, Mary, Jain, Aarti, Davies, D. Huw, Vásquez-Jiménez, Juan M., Herrera, Sonia M., Oñate, José, Felgner, Philip L., Herrera, Sócrates, Arévalo-Herrera, Myriam
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Malaria sterile immunity has been reproducibly induced by immunization with Plasmodium radiation-attenuated sporozoites (RAS). Analyses of sera from RAS-immunized individuals allowed the identification of P. falciparum antigens, such as the circumsporozoite protein (CSP), the basis for the RTS, S and R21Matrix-M vaccines. Similar advances in P. vivax ( Pv ) vaccination have been elusive. We previously reported 42% (5/12) of sterile protection in malaria-unexposed, Duffy-positive (Fy +) volunteers immunized with Pv RAS followed by a controlled human malaria infection (CHMI). Using a custom protein microarray displaying 515 Pv antigens, we found a significantly higher reactivity to Pv CSP and one hypothetical protein (PVX_089630) in volunteers protected against P. vivax infection. In mock-vaccinated Fy + volunteers, a strong antibody response to CHMI was also observed. Although the Fy- volunteers immunized with non-irradiated Pv -infected mosquitoes (live sporozoites) did not develop malaria after CHMI, they recognized a high number of antigens, indicating the temporary presence of asexual parasites in peripheral blood. Together, our findings contribute to the understanding of the antibody response to P.   vivax infection and allow the identification of novel parasite antigens as vaccine candidates. Trial registration: ClinicalTrials.gov number: NCT 01082341.
ISSN:2045-2322
2045-2322
DOI:10.1038/s41598-024-53175-0